Search research articles
Contact Us
Filters
Showing results (101-110 of 113) with videos related to
Page
of 12
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 28, 2021
Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513
E Gabriela Chiorean, Katherine A Guthrie, Philip A Philip, et al.
Cell Reports. Medicine
|
May 7, 2026
HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial results
David A Braun, Marcus S Noel, Ryan H Moy, et al.
British Journal of Pharmacology
|
April 11, 2006
GW627368X ((N-{2-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]acetyl} benzene sulphonamide): a novel, potent and selective prostanoid EP4 receptor antagonist
Richard J Wilson, Gerard M P Giblin, Susan Roomans, et al.
The Pediatric Infectious Disease Journal
|
June 29, 2007
Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia
John S Tam, Maria Rosario Z Capeding, Lucy Chai See Lum, et al.
Cancer Research Communications
|
February 5, 2025
A Phase 2 Study of Sotigalimab, a CD40 Agonist Antibody, plus Concurrent Chemoradiation as Neoadjuvant Therapy for Esophageal and Gastroesophageal Junction Cancers
Andrew H Ko, Joseph Chao, Marcus S Noel, et al.
Eclinicalmedicine
|
March 27, 2023
Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial
Tanios Bekaii-Saab, Takuji Okusaka, David Goldstein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 19, 2019
Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies
Gerald Falchook, Seth Rosen, Patricia LoRusso, et al.
British Journal of Cancer
|
June 25, 2014
Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer
A F Hezel, M S Noel, J N Allen, et al.
Cancer
|
April 20, 2026
Phase 2 trial of exercise and low-dose ibuprofen for cancer-related cognitive impairment in patients receiving chemotherapy
Michelle C Janelsins, Riham A Alieldin, Tyler Holler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 15, 2022
Adjuvant <i>nab</i>-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial
Margaret A Tempero, Uwe Pelzer, Eileen M O'Reilly, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 113) with videos related to
Sort By:
Page
of 12
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 28, 2021
Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513
E Gabriela Chiorean, Katherine A Guthrie, Philip A Philip, et al.
Cell Reports. Medicine
|
May 7, 2026
HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial results
David A Braun, Marcus S Noel, Ryan H Moy, et al.
British Journal of Pharmacology
|
April 11, 2006
GW627368X ((N-{2-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]acetyl} benzene sulphonamide): a novel, potent and selective prostanoid EP4 receptor antagonist
Richard J Wilson, Gerard M P Giblin, Susan Roomans, et al.
The Pediatric Infectious Disease Journal
|
June 29, 2007
Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia
John S Tam, Maria Rosario Z Capeding, Lucy Chai See Lum, et al.
Cancer Research Communications
|
February 5, 2025
A Phase 2 Study of Sotigalimab, a CD40 Agonist Antibody, plus Concurrent Chemoradiation as Neoadjuvant Therapy for Esophageal and Gastroesophageal Junction Cancers
Andrew H Ko, Joseph Chao, Marcus S Noel, et al.
Eclinicalmedicine
|
March 27, 2023
Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial
Tanios Bekaii-Saab, Takuji Okusaka, David Goldstein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 19, 2019
Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies
Gerald Falchook, Seth Rosen, Patricia LoRusso, et al.
British Journal of Cancer
|
June 25, 2014
Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer
A F Hezel, M S Noel, J N Allen, et al.
Cancer
|
April 20, 2026
Phase 2 trial of exercise and low-dose ibuprofen for cancer-related cognitive impairment in patients receiving chemotherapy
Michelle C Janelsins, Riham A Alieldin, Tyler Holler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 15, 2022
Adjuvant <i>nab</i>-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial
Margaret A Tempero, Uwe Pelzer, Eileen M O'Reilly, et al.
Page
of 12